{"groups":[{"description":"VELCADE 1.3 mg/m\\^2 administered by subcutaneous injection on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.","id":"FG000","title":"VELCADE Subcutaneous"},{"description":"VELCADE 1.3 mg/m\\^2 administered by intravenous infusion on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles.","id":"FG001","title":"VELCADE Intravenous"}],"periods":[{"milestones":[{"achievements":[{"comment":"One patient randomized and not dosed","groupId":"FG000","numSubjects":"148"},{"groupId":"FG001","numSubjects":"74"}],"type":"STARTED"},{"achievements":[{"comment":"Completed 8 cycles","groupId":"FG000","numSubjects":"81"},{"comment":"Completed 8 cycles","groupId":"FG001","numSubjects":"39"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"67"},{"groupId":"FG001","numSubjects":"35"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}